[Form 4] Cidara Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Cidara Therapeutics, Inc. (CDTX) – Form 4 insider filing dated 06/18/2025.

Director Ryan Spencer reported the grant of a non-derivative stock option covering 11,100 common shares. The option carries an exercise price of $21.31 and will vest in full on the earlier of (i) 18 June 2026 or (ii) the day prior to the company’s 2026 annual shareholders meeting. The award expires on 17 June 2035. Following the transaction, Mr. Spencer beneficially owns 11,100 derivative securities, all held directly. No common shares were bought or sold in the open market, and no other classes of securities were affected.

The filing is a routine disclosure of an equity incentive granted to a non-employee director and does not indicate any change in the company’s operating or financial outlook.

Insights

Corporate Governance Analyst

TL;DR: Routine director option grant; limited market impact.

This Form 4 records a standard equity incentive for Director Ryan Spencer—11,100 stock options at $21.31, vesting over one year. Such grants are typical board-level compensation tools designed to align directors with shareholder interests. The absence of open-market buying or selling, and the modest size relative to Cidara’s share count, means little immediate signaling value. Investors should view the filing as neutral, with no direct implications for liquidity, capital structure, or earnings.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Spencer Ryan

(Last) (First) (Middle)

C/O CIDARA THERAPEUTICS, INC.

6310 NANCY RIDGE DRIVE SUITE 101

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cidara Therapeutics, Inc. [ CDTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$21.31	06/18/2025		A		11,100		(1)	06/17/2035	Common Stock	11,100	$0	11,100	D

Explanation of Responses:

1. The shares subject to the option shall vest on the earlier of (i) June 18, 2026 or (ii) the day prior to the date of the Issuer's 2026 annual meeting of stockholders.

Remarks:

	/s/ Shane Ward, Attorney-in-Fact	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for Cidara Therapeutics (CDTX)?

Ryan Spencer, a director of Cidara Therapeutics, filed the Form 4.

What security was involved in the reported transaction for CDTX?

A stock option covering 11,100 shares of Cidara common stock was granted.

What is the exercise price and expiration date of the option?

The exercise price is $21.31 per share and the option expires on 06/17/2035.

When will the option granted to Ryan Spencer vest?

It vests on the earlier of 06/18/2026 or the day before the 2026 annual shareholders meeting.

Did the director purchase or sell any CDTX shares in the open market?

No. The filing only reports an equity award grant; no open-market transactions occurred.